0 rating

Metabolomics and IBD

Diane R Hildebrand, MB ChB, MRCS(Ed)1, Natasha P Ross, MB ChB, MRCS(Ed)1, and Angus JM Watson, MB ChB, FRCS(Ed), FRCS(Gen. Surg.)1,2
Int J Clin Rev 2012;02:04    doi: 10.5275/ijcr.2012.02.04

IBD is a chronic inflammatory condition with a high incidence in Northern Europe. Current biological markers are inadequate for detecting, phenotyping, and monitoring the disease. It is therefore imperative to find novel biomarkers that will not only help with diagnosis but that will also shed further light on the pathogenesis of IBD. Metabolomics is an emerging science that is increasingly being utilized for biomarker discovery. Here, we discuss the potential utility of metabolomics in Crohn’s disease and ulcerative colitis.

Return to top

RELATED ARTICLES IN
REMEDICA JOURNALS